Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study
Javier Garciá Corbacho(Breast Cancer Research Foundation), Francesco Schettini(Breast Cancer Research Foundation), Iván Victoria(Hospital Clínic de Barcelona), Oleguer Castillo(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Azucena E. González Navarro(Hospital Clínic de Barcelona), Neus Basté(Hospital Clínic de Barcelona), Núria Viñolas(Hospital Clínic de Barcelona), Miquel Nogué(Hospital General de Granollers), Patricia Galván(Vall d'Hebron Institute of Oncology), Andrea Modrego-Sánchez(Research Institute Hospital 12 de Octubre), Manel Juan(Hospital Sant Joan de Déu Barcelona), Paula Blasco(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Esther Sanfeliu(Hospital Clínic de Barcelona), Tamara Saurí(Hospital Clínic de Barcelona), Laura Angelats(Hospital Clínic de Barcelona), Alberto Indacochea(Hospital General de Granollers), David Pesántez(Hospital Clínic de Barcelona), Aleix Prat(Hospital Clínic de Barcelona), Bárbara Adamo(Hospital Clínic de Barcelona), Debora Moreno(Hospital Clínic de Barcelona), Laura Mezquita(Hospital Clínic de Barcelona)
Cited by 19
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
|Breast Cancer Research|2010|2.1k
Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
|Nature|2011|1.5k
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
|Annals of Oncology|2018|1.2k